Results 271 to 280 of about 47,533 (300)
Some of the next articles are maybe not open access.
The cellular pharmacology of oxaliplatin resistance
European Journal of Cancer, 2002Oxaliplatin is a third generation platinum compound that differs from cisplatin and carboplatin in having a broader spectrum of antitumour activity. Molecular studies suggest that oxaliplatin adducts are recognised and processed differently than those produced by the earlier generation Pt-containing drugs.
S B Howell
exaly +3 more sources
Gastric Cancer, 2021
The attainment of drug resistance in gastric cancer (GC) is a problematic issue. Although many studies have shown that cancer stem cells (CSCs) play an important role in the acquisition of drug resistance, there is no clinically available biomarker for predicting oxaliplatin (L-OHP) resistance in relation to CSCs.
Kenji Harada +13 more
openaire +2 more sources
The attainment of drug resistance in gastric cancer (GC) is a problematic issue. Although many studies have shown that cancer stem cells (CSCs) play an important role in the acquisition of drug resistance, there is no clinically available biomarker for predicting oxaliplatin (L-OHP) resistance in relation to CSCs.
Kenji Harada +13 more
openaire +2 more sources
In vitro studies on the mechanisms of oxaliplatin resistance
Cancer Chemotherapy and Pharmacology, 2001We have previously reported that elevation of glutathione mediated by gamma-glutamyl transpeptidase is one mechanism of oxaliplatin resistance. This study explored other potential oxaliplatin resistance mechanisms with two aims: (1) to identify the differences between cisplatin and oxaliplatin in terms of drug accumulation, DNA-Pt adduct formation and ...
Suzanne Hector +2 more
exaly +3 more sources
JBIC Journal of Biological Inorganic Chemistry, 2017
Oxaliplatin is the backbone of chemotherapy for advanced colorectal cancer and undergoes clinical trials for treatment of other tumour entities. However, acquired resistance is a major hurdle. Confocal microscopy is a useful tool to get an insight into the mechanisms of resistance but it requires fluorescent compounds. This work describes the synthesis
Kalayda, Ganna V. +3 more
openaire +2 more sources
Oxaliplatin is the backbone of chemotherapy for advanced colorectal cancer and undergoes clinical trials for treatment of other tumour entities. However, acquired resistance is a major hurdle. Confocal microscopy is a useful tool to get an insight into the mechanisms of resistance but it requires fluorescent compounds. This work describes the synthesis
Kalayda, Ganna V. +3 more
openaire +2 more sources
MT2A Promotes Oxaliplatin Resistance in Colorectal Cancer Cells
Cell Biochemistry and Biophysics, 2020We aimed to understand the molecular mechanism underlying the incidence of Oxaliplatin resistance in colorectal cancer. The Oxaliplatin-resistant (OR) HT29 colorectal cell line was established by long-term exposure to Oxaliplatin. Cell viability and proliferation were determined by the 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide and ...
Zhicheng Zhao, Guojing Zhang, Weidong Li
openaire +2 more sources
Clinical Cancer Research, 2007
AbstractPurpose: To establish whether cetuximab, a chimeric IgG1 antibody targeting epidermal growth factor receptor, has the potential to restore responsiveness to oxaliplatin in preclinical cancer models, as has been shown with irinotecan in irinotecan refractory metastatic colorectal cancer patients.Experimental Design: The effects of cetuximab and ...
Marie, Prewett +6 more
openaire +2 more sources
AbstractPurpose: To establish whether cetuximab, a chimeric IgG1 antibody targeting epidermal growth factor receptor, has the potential to restore responsiveness to oxaliplatin in preclinical cancer models, as has been shown with irinotecan in irinotecan refractory metastatic colorectal cancer patients.Experimental Design: The effects of cetuximab and ...
Marie, Prewett +6 more
openaire +2 more sources
Txr1: an important factor in oxaliplatin resistance in gastric cancer
Medical Oncology, 2013Oxaliplatin-based chemotherapy is the main treatment regimen for gastric cancer (GC), but can fail because of drug resistance. We investigated the role of a recently identified drug-resistance gene, taxol-resistant gene 1 (Txr1), in oxaliplatin resistance. A retrospective study based on banked tissue was carried out.
Jingtao, Bi +8 more
openaire +2 more sources
The involvement of Aurora‐A and p53 in oxaliplatin‐resistant colon cancer cells
Journal of Cellular Biochemistry, 2023AbstractResistance to chemotherapy is the deadlock in cancer treatment. In this study, we used wild‐type LOVO (LOVOWT), a human colon cancer cell line, and the oxaliplatin‐resistant sub‐clone LOVOOR cells to investigate the molecular mechanisms of the development of drug resistance in colon cancer.
Mei‐Chih Chen +7 more
openaire +2 more sources
Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance [PDF]
, 2023 内容の要約
openaire
Role of Dicer in regulating oxaliplatin resistance of colon cancer cells
Biochemical and Biophysical Research Communications, 2018Colorectal cancer (CRC) is a major health problem due to its high mortality rate. The incidence of CRC is increasing in young individuals. Oxaliplatin (OXA) is an approved third-generation drug and is used for first-line chemotherapy in CRC. Although current standard chemotherapy improves the overall survival of CRC patients, an increasing number of ...
Hui-Huang Lai +3 more
openaire +2 more sources